We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.71B
AUM Growth
+$23.5M
Cap. Flow
+$140M
Cap. Flow %
8.18%
Top 10 Hldgs %
56.71%
Holding
87
New
17
Increased
22
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$30M
2
XNCR icon
Xencor
XNCR
+$20.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20M
4
GH icon
Guardant Health
GH
+$19.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$17M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$67.8M
2
UTHR icon
United Therapeutics
UTHR
+$18.1M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$15.8M
4
ZTS icon
Zoetis
ZTS
+$14.8M
5
EXEL icon
Exelixis
EXEL
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$290M 16.93%
3,102,960
– –
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$256M 14.94%
1,953,077
– –
VERA icon
3
Vera Therapeutics
VERA
$2.54B
$77.9M 4.55%
2,914,776
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$67.2M 3.93%
499,824
– –
SPY icon
5
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$47.5M 2.77%
+100,000
New +$45.9M
JBIO
6
Jade Biosciences
JBIO
$1.22B
$44.3M 2.59%
107,391
– –
ABBV icon
7
AbbVie
ABBV
$458B
$42.2M 2.47%
312,018
+39,418
+14% +$4.66M
QQQ icon
8
PUT
Invesco QQQ Trust
QQQ
$455B
$39.8M 2.32%
+100,000
New +$38.6M
YMAB
9
DELISTED
Y-mAbs Therapeutics
YMAB
$35.6M 2.08%
2,194,278
– –
IWM icon
10
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$33.4M 1.95%
+150,000
New +$33.9M
RGNX icon
11
Regenxbio
RGNX
$623M
$33M 1.93%
1,008,081
+880,488
+690% +$30M
TVTX icon
12
Travere Therapeutics
TVTX
$5.33B
$32.3M 1.89%
1,040,858
+603,578
+138% +$17M
UTHR icon
13
United Therapeutics
UTHR
$26.3B
$28M 1.64%
129,754
-92,340
-42% -$18.1M
HRTX icon
14
Heron Therapeutics
HRTX
$86.3M
$26.8M 1.56%
2,933,351
+632,172
+27% +$6.45M
CCXI
15
DELISTED
ChemoCentryx, Inc.
CCXI
$26.6M 1.56%
731,222
+213,514
+41% +$7.5M
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$26.3M 1.53%
245,182
+63,322
+35% +$6.62M
ALGN icon
17
Align Technology
ALGN
$12B
$25.1M 1.46%
38,159
-8,841
-19% -$5.68M
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$23.9M 1.4%
221,792
+64,305
+41% +$7.01M
GH icon
19
Guardant Health
GH
$19.5B
$23.3M 1.36%
232,563
+192,563
+481% +$19.9M
XNCR icon
20
Xencor
XNCR
$1.44B
$21.5M 1.26%
+537,030
New +$20.4M
CYTK icon
21
Cytokinetics
CYTK
$11B
$21.2M 1.24%
464,366
+37,734
+9% +$1.46M
BCRX icon
22
BioCryst Pharmaceuticals
BCRX
$2.37B
$20.9M 1.22%
+1,510,473
New +$20M
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.84B
$20.8M 1.22%
951,226
+537,385
+130% +$9.93M
IRTC icon
24
iRhythm Holdings
IRTC
$3.59B
$19.9M 1.16%
+168,882
New +$15.5M
DXCM icon
25
DexCom
DXCM
$27.6B
$17.4M 1.02%
129,616
-19,448
-13% -$2.79M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2021 Portfolio in Review

As of Q4 2021, Sofinnova Investments held 87 positions worth $1.71B, up 1.4% from $1.69B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $140M of net new capital in Q4 2021, opening 17 new positions and adding to 22 existing holdings. Its largest new stake was Xencor: 537,030 shares worth $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was United Therapeutics, an estimated $18.1M trimmed.

  • Sofinnova Investments's largest Q4 2021 buy was Xencor: 537,030 shares worth $21.5M.
  • Sofinnova Investments added most to Regenxbio in Q4 2021, an estimated $30M increase.
  • Sofinnova Investments's biggest Q4 2021 reduction was United Therapeutics, cutting an estimated $18.1M.
  • Sofinnova Investments fully exited AstraZeneca in Q4 2021, selling an estimated $67.8M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.71B portfolio in Q4 2021.
  • Sofinnova Investments opened 17 new positions and closed 17 in Q4 2021.
  • Sofinnova Investments's portfolio value rose 1.4% quarter-over-quarter to $1.71B.

Based on Sofinnova Investments's 13F filing for Q4 2021, filed 14 Feb 2022.